Celsion (NASDAQ:CLSN) Lowered to “Sell” at ValuEngine

Celsion (NASDAQ:CLSN) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report issued on Thursday, June 6th, ValuEngine reports.

CLSN has been the topic of several other reports. Oppenheimer reissued a “buy” rating on shares of Celsion in a research note on Tuesday, March 19th. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a research note on Monday, June 3rd.

Shares of CLSN stock traded down $0.01 during trading hours on Thursday, hitting $1.82. The stock had a trading volume of 93,558 shares, compared to its average volume of 111,460. Celsion has a one year low of $1.35 and a one year high of $3.34. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 0.51. The business has a 50-day simple moving average of $1.96. The stock has a market capitalization of $37.28 million, a PE ratio of -2.68 and a beta of 2.10.

Celsion (NASDAQ:CLSN) last issued its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). Celsion had a negative return on equity of 65.35% and a negative net margin of 1,954.60%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts forecast that Celsion will post -1.04 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of CLSN. BlackRock Inc. grew its stake in shares of Celsion by 21.9% during the fourth quarter. BlackRock Inc. now owns 142,426 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 25,548 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Celsion by 40.9% during the third quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Celsion by 40.9% during the third quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the last quarter. 4.76% of the stock is currently owned by institutional investors.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Featured Article: What is Forex?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.